Virtual care is growing in the inpatient setting

The U.S. Food and Drug Administration's validation requirements process for drug development is a good model for healthcare artificial intelligence governance, explains Michael Abrams, managing partner at Numerof & Associates.

Todd Van Meter, CEO of Accuity, says that when partnering with clients, initial clinical denial rates are nearly cut in half and following an appeals process using an AI-driven platform, the final denial rates end up at 1% to 1.5%.

The chief information officer of the 25-bed New Mexico nonprofit discusses plan for some new clinical automation tools. He also describes how he's using AI to help with network defense, and how that's enabling gains in other areas.